The VX-670 oligonucleotide engages the CUG repeat RNA and liberates bound splicing factors (i.e., MBNL1). Through this mechanism, VX-670 aims to correct mis-splicing, and is being investigated to address the underlying cause of disease.

A groundbreaking clinical trial is underway to assess the potential of VX-670, a new drug designed to treat Myotonic Dystrophy Type 1 (DM1). This Phase 1/2 study aims to investigate the safety, tolerability, and effectiveness of VX-670 in adult patients with DM1.

Jan 7, 2024 · VX-670 is an oligonucleotide that targets the underlying cause of DM1, linked to a cyclic peptide that promotes effective delivery into cells. DM1 is the most prevalent muscular dystrophy in adults with ~110,000 people living with the disease in the U.S. and Europe.

A Phase 1/2, Randomized, Double-blind, Placebo‑controlled Single- and Multiple‑dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX‑670 in Adult Subjects with Myotonic Dystrophy Type 1

We are investigating VX-670, an oligonucleotide approach using an intracellular Endosomal Escape Vehicle (EEV™) aimed at targeting the underlying cause of DM1.

Apr 10, 2025 · An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I.

The PCI PED approved Vx 670 is a small, sleek, and secure handheld payment device designed specifically for wireless, customer-facing payment. VeriFone's patent-pending MAXui design provides the largest user interface in the smallest form factor with a large, white backlit display and large blue backlit keys.

Dec 12, 2024 · The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Customers can enjoy longer time in their table as the VX 670 Wi-Fi technology can handle on-the-table payments. An integrated printer provides receipts in a whisper-like manner. Combination of high quality POS devices in this terminal solves merchant’s point of sale issues.

VX 670 is an investigational medication being studied for its potential to treat myotonic dystrophy type 1 (DM1). The trial aims to assess how safe and tolerable this medication is when given in single and multiple doses to adults with DM1.